A retrospective analysis of locally advanced EGFR-mutated NSCLC patients with durvalumab after chemoradiotherapy

被引：0
|
作者：
Uchida, Yoshiyasu [1 ]
Ninomiya, Takashi [1 ]
Harada, Daijiro [1 ]
Kozuki, Toshiyuki [1 ]
机构：
[1] Natl Hosp Org Shikoku Canc Ctr, Dept Thorac Oncol & Med, Matsuyama, Ehime, Japan
来源：
ANNALS OF ONCOLOGY | 2022年 / 33卷
关键词：
D O I：
10.1016/j.annonc.2022.05.126
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
MO11-4
引用
收藏
页码：S488 / S488
页数：1
相关论文
共 50 条
  • [31] A Retrospective Comparison of Survival Outcomes in EGFR-mutated, NSCLC Patients on Osimertinib plus /- Brain Metastases
    Litt, I.
    Gibson, A.
    Dean, M.
    Elegbede, A.
    Bebb, G.
    Cheung, W.
    Pabani, A.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S232 - S232
  • [32] EGFR-Mutated NSCLC: Clinical Practice Assessment and Gap Analysis
    Herrmann, Tara
    Hamarstrom, Elaine
    Ramalingam, Suresh
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1218 - S1219
  • [33] Mortality among EGFR-mutated advanced NSCLC patients after frontline osimertinib treatment: A real-world, US attrition analysis
    Girard, N.
    Leighl, N.
    Ohe, Y.
    Kim, T. M.
    Demirdjian, L.
    Bourla, A. B.
    Sultan, A. Abdul
    Mahadevia, P.
    Bauml, J. M.
    Sabari, J.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (04) : S51 - S52
  • [34] Hematological parameters in EGFR-mutated advanced NSCLC patients treated with TKIs: predicting survival and toxicity
    Jokic, Vera
    Savic-Vujovic, Katarina
    Spasic, Jelena
    Stanic, Nemanja
    Marinkovic, Mladen
    Radosavljevic, Davorin
    Cavic, Milena
    EXPERT REVIEW OF ANTICANCER THERAPY, 2021, 21 (06) : 673 - 679
  • [35] Economic Analysis of First-Line Treatment with Erlotinib in an EGFR-Mutated Population with Advanced NSCLC
    Vergnenegre, Alain
    Massuti, Bartomeu
    de Marinis, Filippo
    Carcereny, Enric
    Felip, Enriqueta
    Do, Pascal
    Miguel Sanchez, Jose
    Paz-Arez, Luis
    Chouaid, Christos
    Rosell, Rafael
    JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (06) : 801 - 807
  • [36] EGFR-mutated NSCLC: A roadmap to treatment sequences
    Girard, Nicolas
    MED, 2024, 5 (09): : 1044 - 1047
  • [37] Efficacy of durvalumab after chemoradiotherapy with daily low-dose carboplatin for unresectable locally advanced NSCLC
    Kawajiri, Kazuki
    Shinno, Yuki
    Shirasawa, Masayuki
    Sato, Daiki
    Takeyasu, Yuki
    Torasawa, Masahiro
    Matsumoto, Yuji
    Masuda, Ken
    Okuma, Yusuke
    Yoshida, Tatsuya
    Goto, Yasushi
    Horinouchi, Hidehito
    Yamamoto, Noboru
    Ohe, Yuichiro
    ANNALS OF ONCOLOGY, 2022, 33 : S488 - S488
  • [38] Resistance landscape to almonertinib in EGFR-mutated NSCLC
    Tian, M.
    Lu, Z.
    Chen, S.
    Lu, G.
    Bu, F.
    Deng, W.
    Ding, R.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1017 - S1017
  • [39] The Efficacy of Durvalumab after Concurrent Chemoradiotherapy for EGFR-Mutated Stage III NonSmall Cell Lung Cancer (NEJ063)
    Kida, G.
    Fujisaki, T.
    Miyauchi, E.
    Kikuchi, H.
    Hommura, F.
    Yokoo, K.
    Tanaka, H.
    Kikuchi, T.
    Jingu, D.
    Sugisaka, J.
    Watanabe, K.
    Yoshimura, N.
    Nakagawa, T.
    Nogawa, H.
    Sato, M.
    Nakazawa, K.
    Soda, S.
    Takigami, A.
    Arai, D.
    Masubuchi, K.
    Miura, Y.
    Miura, Y.
    Nagai, Y.
    Matsumoto, N.
    Oba, T.
    Namba, Y.
    Ashinuma, H.
    Saito, G.
    Kamimura, M.
    Takahashi, S.
    Isobe, K.
    Miyawaki, T.
    Nishiyama, K.
    Sakashita, H.
    Nozaki, K.
    Inomata, M.
    Umeda, Y.
    Tateishi, K.
    Tetsumoto, S.
    Tamiya, M.
    Tsubata, Y.
    Masuda, K.
    Matsumoto, N.
    Obata, H.
    Yamaji, Y.
    Harada, M.
    Ohnishi, H.
    Nakao, A.
    Morita, S.
    Maemondo, M.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S182 - S183
  • [40] Safety and tolerability of lazertinib and in combination with amivantamab in advanced EGFR-mutated Japanese NSCLC
    Goto, Koichi
    Hida, Toyoaki
    Funami, Nobuyuki
    Iwasawa, Ryota
    Mita, Sachiko
    Yamashita, Aimi
    Imanaka, Keiichiro
    Kitani, Sumiko
    Ohe, Yuichiro
    ANNALS OF ONCOLOGY, 2021, 32 : S317 - S317
12345